REGENERON PHARMACEUTICALS, INC.【REGN】Income statement

Market cap

$86.5B

P/E ratio

	2010/12	2011/12	2012/12	2013/12	2014/12	2015/12	2016/12	2017/12	2018/12	2019/12	2020/12	2021/12	2022/12	2023/12	2024/12
Revenue	459	446	1,378	2,105	2,820	4,104	4,860	5,872	6,711	7,863	8,497	16,072	12,173	13,117	14,202
Revenue growth (%)	-
Cost of revenue	2	4	84	118	129	242	195	203	-	-	-	-	-	-	-
Research & development	489	530	626	860	1,271	1,621	2,052	2,075	2,186	3,037	2,735	2,908	3,593	4,439	5,132
Selling, general & administrative	65	117	211	329	505	839	1,178	1,320	1,556	1,835	1,346	1,825	2,116	2,631	2,954
Operating margin (%)
Operating income	-97	-205	458	760	838	1,252	1,331	2,080	2,534	2,210	3,577	8,947	4,739	4,047	3,991
Operating expenses	557	651	921	1,345	1,981	2,852	3,530	3,793	4,176	5,654	4,921	7,125	7,434	9,070	10,211
Income before tax	-104	-223	414	713	776	1,225	1,330	2,079	2,554	2,429	3,810	9,326	4,859	4,199	4,780
Pretax margin (%)	-22.8	-50	30.1	33.9	27.5	29.9	27.4	35.4	38.1	30.9	44.8	58	39.9	32	33.7
Provision for income taxes	-	-1	-336	289	428	589	434	880	109	313	297	1,251	520	246	367
Effective tax rate (%)	-
Net income	-104	-222	750	424	348	636	896	1,199	2,444	2,116	3,513	8,075	4,338	3,954	4,413
Net income margin (%)
Earnings per share	-	-	7.92	4.33	3.46	6.17	8.55	11.27	22.65	19.38	32.65	76.4	40.51	37.05	40.9
Diluted EPS	-	-	6.75	3.81	3.07	5.52	7.7	10.34	21.29	18.46	30.52	71.97	38.22	34.77	38.34
EBITDA		-
EBITDA margin (%)		-